These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 28934253)

  • 41. Apolipoprotein A-V is a potential target for treating coronary artery disease: evidence from genetic and metabolomic analyses.
    Ibi D; Boot M; Dollé MET; Jukema JW; Rosendaal FR; Christodoulides C; Neville MJ; Koivula R; Rensen PCN; Karpe F; Noordam R; Willems van Dijk K
    J Lipid Res; 2022 May; 63(5):100193. PubMed ID: 35278410
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A VOYAGER Meta-Analysis of the Impact of Statin Therapy on Low-Density Lipoprotein Cholesterol and Triglyceride Levels in Patients With Hypertriglyceridemia.
    Karlson BW; Palmer MK; Nicholls SJ; Lundman P; Barter PJ
    Am J Cardiol; 2016 May; 117(9):1444-8. PubMed ID: 26969416
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Apolipoprotein A5, a unique modulator of fasting and postprandial triglycerides.
    May-Zhang L; Liu M; Black D; Tso P
    Biochim Biophys Acta Mol Cell Biol Lipids; 2022 Sep; 1867(9):159185. PubMed ID: 35644522
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy and safety of rosuvastatin and fenofibric acid combination therapy versus simvastatin monotherapy in patients with hypercholesterolemia and hypertriglyceridemia: a randomized, double-blind study.
    Roth EM; McKenney JM; Kelly MT; Setze CM; Carlson DM; Gold A; Stolzenbach JC; Williams LA; Jones PH
    Am J Cardiovasc Drugs; 2010; 10(3):175-86. PubMed ID: 20524719
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Attaining United States and European guideline LDL-cholesterol levels with simvastatin in patients with coronary heart disease (the GOALLS study).
    Garmendia F; Brown AS; Reiber I; Adams PC
    Curr Med Res Opin; 2000; 16(3):208-19. PubMed ID: 11191012
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Rosa rugosa flavonoids exhibited PPARα agonist-like effects on genetic severe hypertriglyceridemia of mice.
    Baiyisaiti A; Wang Y; Zhang X; Chen W; Qi R
    J Ethnopharmacol; 2019 Aug; 240():111952. PubMed ID: 31100436
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Apolipoprotein A5 regulates intracellular triglyceride metabolism in adipocytes.
    Zheng XY; Yu BL; Xie YF; Zhao SP; Wu CL
    Mol Med Rep; 2017 Nov; 16(5):6771-6779. PubMed ID: 28901468
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Apolipoprotein A5 internalized by human adipocytes modulates cellular triglyceride content.
    Zheng XY; Zhao SP; Yu BL; Wu CL; Liu L
    Biol Chem; 2012 Mar; 393(3):161-7. PubMed ID: 22718631
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Differential gene expression in mouse primary hepatocytes exposed to the peroxisome proliferator-activated receptor alpha agonists.
    Guo L; Fang H; Collins J; Fan XH; Dial S; Wong A; Mehta K; Blann E; Shi L; Tong W; Dragan YP
    BMC Bioinformatics; 2006 Sep; 7 Suppl 2(Suppl 2):S18. PubMed ID: 17118139
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Xuezhikang, an extract from red yeast rice, attenuates vulnerable plaque progression by suppressing endoplasmic reticulum stress-mediated apoptosis and inflammation.
    Shen L; Sun Z; Chu S; Cai Z; Nie P; Wu C; Yuan R; Hu L; He B
    PLoS One; 2017; 12(11):e0188841. PubMed ID: 29190732
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Delta5 desaturase mRNA levels are increased by simvastatin via SREBP-1 at early stages, not via PPARalpha, in THP-1 cells.
    Risé P; Ghezzi S; Carissimi R; Mastromauro F; Petroni A; Galli C
    Eur J Pharmacol; 2007 Oct; 571(2-3):97-105. PubMed ID: 17655842
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Toxicological evaluation of, red rice yeast extract, Xuezhikang: Acute, 26-week chronic and genotoxicity studies.
    Gao Y; Chen X; Li C; Wang H; Tian J; Fu F
    Regul Toxicol Pharmacol; 2020 Jul; 114():104654. PubMed ID: 32278069
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Overexpression of salusin‑α upregulates AdipoR2 and activates the PPARα/ApoA5/SREBP‑1c pathway to inhibit lipid synthesis in HepG2 cells.
    Zhang H; Yang C; Wang S; Xu A; Zhang Q; Duan X; Gong G; Wang Y
    Int J Mol Med; 2023 May; 51(5):. PubMed ID: 37026514
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Disruption of hepatic lipid homeostasis in mice after amiodarone treatment is associated with peroxisome proliferator-activated receptor-alpha target gene activation.
    McCarthy TC; Pollak PT; Hanniman EA; Sinal CJ
    J Pharmacol Exp Ther; 2004 Dec; 311(3):864-73. PubMed ID: 15265979
    [TBL] [Abstract][Full Text] [Related]  

  • 55. APOA5 deficiency causes hypertriglyceridemia by reducing amounts of lipoprotein lipase in capillaries.
    Yang Y; Konrad RJ; Ploug M; Young SG
    J Lipid Res; 2024 Jul; 65(7):100578. PubMed ID: 38880127
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Apolipoprotein A5: Extracellular and Intracellular Roles in Triglyceride Metabolism.
    Forte TM; Ryan RO
    Curr Drug Targets; 2015; 16(12):1274-80. PubMed ID: 26028042
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Apolipoprotein A-V deficiency results in marked hypertriglyceridemia attributable to decreased lipolysis of triglyceride-rich lipoproteins and removal of their remnants.
    Grosskopf I; Baroukh N; Lee SJ; Kamari Y; Harats D; Rubin EM; Pennacchio LA; Cooper AD
    Arterioscler Thromb Vasc Biol; 2005 Dec; 25(12):2573-9. PubMed ID: 16166565
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Correlation of non-high-density lipoprotein cholesterol and low-density lipoprotein cholesterol with apolipoprotein B during simvastatin + fenofibrate therapy in patients with combined hyperlipidemia (a subanalysis of the SAFARI trial).
    Grundy SM; Vega GL; Tomassini JE; Tershakovec AM
    Am J Cardiol; 2009 Aug; 104(4):548-53. PubMed ID: 19660610
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The olive constituent oleuropein, as a PPARα agonist, markedly reduces serum triglycerides.
    Malliou F; Andreadou I; Gonzalez FJ; Lazou A; Xepapadaki E; Vallianou I; Lambrinidis G; Mikros E; Marselos M; Skaltsounis AL; Konstandi M
    J Nutr Biochem; 2018 Sep; 59():17-28. PubMed ID: 29960113
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Regulation of lipid and lipoprotein metabolism by PPAR activators.
    Gervois P; Torra IP; Fruchart JC; Staels B
    Clin Chem Lab Med; 2000 Jan; 38(1):3-11. PubMed ID: 10774955
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.